Malaria and Some Polyomaviruses (Sv40, Bk, Jc, and Merkel Cell Viruses) Volume 104

Total Page:16

File Type:pdf, Size:1020Kb

Malaria and Some Polyomaviruses (Sv40, Bk, Jc, and Merkel Cell Viruses) Volume 104 MALARIA AND SOME POLYOMAVIRUSES (SV40, BK, JC, AND MERKEL CELL VIRUSES) VOLUME 104 This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 7-14 February 2012 LYON, FRANCE - 2014 IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS INTRODUCTION TO POLYOMAVIRUSES 1. Discovery BK polyomavirus (BKV) and JC polyomavirus (JCV), were eventually found to chronically In 1953, Ludwik Gross reported that a filter- infect the great majority of humans worldwide able infectious agent could cause salivary cancer (reviewed in Abend et al., 2009; Maginnis & in laboratory mice (Gross, 1953; Stewart et al., Atwood, 2009). The apparent ubiquity of BKV 1957). The cancer-causing agent was found to and JCV makes it difficult to correlate seropos- be a non-enveloped DNA virus that was named itivity for BKV- or JCV-specific antibodies with murine polyomavirus (from the Greek roots specific disease states, such as cancer. poly-, which means “many,” and -oma, which Reports in the past four years have revealed the means “tumours”), for its ability to cause existence of seven more human polyomaviruses. tumours in multiple tissues in experimentally Perhaps the most intriguing of the new species, infected rodents (reviewed in Sweet & Hilleman, named Merkel cell polyomavirus (MCV), was 1960). The discovery spurred renewed interest in discovered through a directed genomic search the idea that viral infections might be a major of an unusual form of skin cancer, Merkel cell cause of cancer in humans. carcinoma (MCC) (Feng et al., 2008). Another By the late 1950s, various investigators had new polyomavirus, trichodysplasia spinulo- succeeded in developing cell culture systems for sa-associated polyomavirus (TSV), was isolated analysing the transforming activities of murine from a rare hyperplastic (but non-neoplastic) polyomavirus in vitro. This work set the stage trichodysplasia spinulosa skin tumour that can for the discovery of the primate polyomavirus occur in transplant patients (van der Meijden simian virus 40 (SV40), which was identified as et al., 2010). Little is currently known about a contaminant in primary cultures of monkey the cancer-causing potential of TSV. Five other kidney cells used to produce vaccines against recently discovered human polyomaviruses – poliovirus (Sweet & Hilleman, 1960; Eddy et al., named WU polyomavirus (WUV), KI polyoma- 1962). Millions of individuals were exposed to virus (KIV), human polyomavirus 6 (HPyV6), infectious SV40 virions present in contaminated HPyV7, and HPyV9 – have not so far been clearly polio vaccines administered between 1955 and associated with human disease states (Allander 1963 (reviewed in Shah & Nathanson, 1976; et al., 2007; Gaynor et al., 2007; Schowalter et al., Dang-Tan et al., 2004). 2010; Sauvage et al., 2011; Scuda et al., 2011). The In 1971, the first two naturally human-tropic remaining Monographs in this Volume will focus polyomaviruses were discovered in specimens on SV40, BKV, JCV, and MCV. from immunocompromised patients (Gardner et al., 1971; Padgett et al., 1971). The two viruses, 121 IARC MONOGRAPHS – 104 Fig. 1.1 Phylogenetic tree of known polyomavirus species Human-derived species are in bold type. Prepared by the Working Group. 122 Introduction to polyomaviruses 2. Taxonomy and phylogeny encompass all the currently known human- and primate-tropic species, while the third genus The exterior structure of the non-envel- includes species thought to be tropic only for oped capsids of members of the viral family birds. The four primate polyomavirus species Polyomaviridae is strikingly similar to the that have been proposed to be potentially impli- capsids of a different family of non-enveloped cated in human cancer (SV40, BKV, JCV, and viruses called the Papillomaviridae. Both families MCV) are all members of the proposed genus carry circular, double-stranded DNA (dsDNA) Orthopolyomavirus. genomes. Based on these considerations, the Although SV40, BKV, and JCV are separate two virus groups were originally classified viral species, they are very closely related to one within a single family, the Papovaviridae (a sigla another, sharing about 70–75% identity at the condensation of PApillomavirus POlyomavirus nucleotide level across the entire genome. MCV is simian VAcuolating). However, sequencing of only distantly related to the SV40 cluster, sharing the genomes of various polyomaviruses and less than 35% nucleotide identity across the papillomaviruses revealed essentially no detect- entire genome (Fig. 1.1). Phylogenetic analyses able sequence homology between the two virus of BKV and JCV isolates from different popula- groups and furthermore showed that the two tions worldwide have shown that the two virus groups had dramatically different genetic organ- species exhibit a geographical pattern of genetic ization. Since the sequencing results indicate that drift that closely resembles proposed patterns of polyomaviruses and papillomaviruses probably prehistoric human migration (reviewed in Yogo never shared a common viral ancestor, they were et al., 2004, 2009). MCV is somewhat more closely officially split into separate viral families. related to murine polyomavirus, with the two Interestingly, several recent reports suggest species sharing about 50% nucleotide identity that polyomaviruses and papillomaviruses may across the complete viral genome. Phylogenetic occasionally recombine with one another to trees based on the nucleotide or amino acid produce viable chimeric viruses with mixed sequences of individual viral gene products give genetic characteristics of both families (Woolford similar results, suggesting that the members et al., 2007). Another recent report documenting of the SV40 cluster diverged from one another a novel viral species that infects eels suggests relatively recently, while the split between MCV that polyomaviruses might also recombine with and members of the SV40 cluster occurred in the members of other families of DNA viruses to much more distant past. produce viable chimeric progeny (Mizutani et al., 2011). The taxonomy of these apparently chimeric viral species is currently undefined. 3. Structure of the virion A recent proposal that is currently being reviewed by the International Committee on The exterior surface of the polyomavirus Taxonomy of Viruses suggests that the various virion is a naked protein capsid composed entirely members of the family Polyomaviridae be of a single virally encoded protein called capsid grouped into separate genera (Johne et al., 2011). viral protein 1 (VP1) (Stehle et al., 1996) (see If approved, this would result in the division of cover photograph). The virion contains a total the current sole genus Polyomavirus into three of 72 pentameric VP1 capsomers arranged on a genera: Orthopolyomavirus, Wukipolyomavirus, T = 7d icosahedral lattice (Yan et al., 1996). VP1 and Avipolyomavirus. The first two genera subunits are folded into a classic eight-stranded β 123 IARC MONOGRAPHS – 104 jellyroll fold that is shared among a wide variety serological analyses of polyomavirus epidemi- of viral capsid proteins and the cellular protein ology (Hamilton et al., 2000; Carter et al., 2003; nucleoplasmin (Stehle et al., 1994; Carrillo-Tripp de Sanjose et al., 2003; Stolt et al., 2003). Purified et al., 2009). The jellyroll, which forms the core polyomavirus VLPs can be immunogenic when of the pentameric VP1 interface, is arranged administered to laboratory animals, raising perpendicular to the spherical virion, such that serum antibody responses capable of neutral- the assembled virion has a distinctive knobby izing native virions in vitro (Goldmann et al., appearance. An additional capsid protein, VP2, 1999; Velupillai et al., 2006; Randhawa et al., as well as its N-truncated isoform VP3, associate 2009). VLPs can even be humorally immuno- with the central lumen of each VP1 capsomer genic in mice in the absence of functional T-cell (Chen et al., 1998). immunity (Vlastos et al., 2003), suggesting that In all extensively studied examples, it appears VLP-based immunogens might be effective in that polyomavirus infectious entry requires inter- immunocompromised human subjects who actions between VP1 and one or more cellular may be at greater risk of polyomavirus-associ- glycans that carry at least one sialic acid residue. ated disease. This suggests that polyomaviruses In several distantly related polyomaviruses, the might be a suitable target for the development binding site for the sialylated glycan receptor is of VLP-based preventive vaccines, similar to the formed by a pocket along the outer rim of the highly successful VLP-based vaccines against apical portion of the VP1 capsomer knob (Stehle hepatitis B virus and human papillomaviruses and Harrison, 1996; Neu et al., 2008; Neu et al., (HPV). 2010). The loops that form the receptor binding pocket vary extensively between polyomavirus species, and even among closely related polyoma- 4. Genomic organization, gene virus subspecies (Luo et al., 2012). This variation products, and replication may reflect selective pressure to evade recog- nition by antibodies that occlude the receptor The circular ~5 kb dsDNA polyomavirus binding site. genome is roughly divided into two oppositely The floor of the canyons between the oriented transcriptional units separated by a capsomer knobs is formed primarily by N- and non-coding control region (NCCR) (reviewed C-terminal arms of VP1. The arms
Recommended publications
  • A Small Molecule Compound IMB-LA Inhibits HIV-1 Infection By
    www.nature.com/scientificreports OPEN A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from Received: 18 May 2015 Accepted: 19 November 2015 antagonizing the host restriction Published: 16 December 2015 factor BST-2 Zeyun Mi1,5,*, Jiwei Ding1,*, Quan Zhang1,*, Jianyuan Zhao2, Ling Ma1, Haisheng Yu6, Zhenlong Liu3, Guangzhi Shan1, Xiaoyu Li1, Jinming Zhou1, Tao Wei2, Liguo Zhang6, Fei Guo4, Chen Liang3 & Shan Cen1 Human BST-2 inhibits HIV-1 replication by tethering nascent virions to the cell surface. HIV-1 codes Vpu that counteracts BST-2 by down-regulating this restriction factor from the cell surface. This important function makes Vpu a potential therapeutic target. Yet, no agents have been reported to block Vpu from antagonizing BST-2. In this study, we report a small molecule compound IMB-LA that abrogates the function of Vpu and thereby strongly suppresses HIV-1 replication by sensitizing the virus to BST-2 restriction. Further studies revealed that IMB-LA specifically inhibits Vpu-mediated degradation of BST-2 and restores the expression of BST-2 at the cell surface. Although IMB-LA does not prevent Vpu from interacting with BST-2 or β-TrCP2-containing ubiquitin E3 ligase, sorting of BST-2 into lysosomes in Vpu-expressing cells is blocked by IMB-LA. Most importantly, HIV-1 release and infection is inhibited by IMB-LA only in BST-2-expressing cells. In summary, results herein demonstrated that IMB-LA could specifically inhibit the degradation of BST-2 induced by Vpu, and impair HIV-1 replication in a BST-2 dependent manner, suggesting the feasibility of utilizing small molecule compounds to disable the antagonist function of Vpu and thereby expose HIV-1 to the restriction by BST-2.
    [Show full text]
  • Oncogenes of DNA Tumor Viruses1
    [CANCER RESEARCH 48. 493-496. February I. 1988] Perspectives in Cancer Research Oncogenes of DNA Tumor Viruses1 Arnold J. Levine Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544 Experiments carried out over the past 10-12 years have the cellular oncogenes. It will attempt to identify where more created a field or approach which may properly be termed the information is required or contradictions appear in the devel molecular basis of cancer. One of its major accomplishments oping concepts. Finally, this communication will examine ex has been the identification and understanding of some of the amples of cooperation between oncogenes and other gene prod functions of a group of cancer-causing genes, the oncogenes. ucts which modify the mode of action of the former. If we are The major path to the oncogenes came from the study of cancer- on the right track, then general principles may well emerge. causing viruses. The oncogenes have been recognized and stud Tumor formation in animals or transformation in cell culture ied by two separate but related groups of virologists focusing has been demonstrated with many different DNA-containing upon either the DNA (1) or RNA (2) tumor viruses (they even viruses (1). In most cases it has been possible to identify one or have separate meetings now that these fields have grown so a few viral genes and their products that are responsible for large). From their studies it has become clear that the oncogenes transformation or, in some cases, tumorigenesis. A list of these of each virus type have very different origins.
    [Show full text]
  • Tätigkeitsbericht 2007/2008
    Tätigkeitsbericht 2007/2008 8 200 / 7 0 20 Tätigkeitsbericht Stiftung bürgerlichen Rechts Martinistraße 52 · 20251 Hamburg Tel.: +49 (0) 40 480 51-0 · Fax: +49 (0) 40 480 51-103 [email protected] · www.hpi-hamburg.de Impressum Verantwortlich Prof. Dr. Thomas Dobner für den Inhalt Dr. Heinrich Hohenberg Redaktion Dr. Angela Homfeld Dr. Nicole Nolting Grafik & Layout AlsterWerk MedienService GmbH Hamburg Druck Hartung Druck + Medien GmbH Hamburg Titelbild Neu gestaltete Fassade des Seuchenlaborgebäudes Tätigkeitsbericht 2007/2008 Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie an der Universität Hamburg Martinistraße 52 · 20251 Hamburg Postfach 201652 · 20206 Hamburg Telefon: +49-40/4 80 51-0 Telefax: +49-40/4 80 51-103 E-Mail: [email protected] Internet: www.hpi-hamburg.de Das Heinrich-Pette-Institut ist Mitglied der Leibniz-Gemeinschaft (WGL) Internet: www.wgl.de Inhaltsverzeichnis Allgemeiner Überblick Vorwort ................................................................................................... 1 Die Struktur des Heinrich-Pette-Instituts .............................................. 2 Modernisierung des HPI erfolgreich abgeschlossen ............................ 4 60 Jahre HPI .............................................................................................. 5 Offen für den Dialog .............................................................................. 6 Preisverleihungen und Ehrungen .......................................................... 8 Personelle Veränderungen in
    [Show full text]
  • Inhibition of HIV-1 by an Anti-Integrase Single-Chain Variable
    Gene Therapy (1999) 6, 660–666 1999 Stockton Press All rights reserved 0969-7128/99 $12.00 http://www.stockton-press.co.uk/gt Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection M BouHamdan1, L-X Duan1, RJ Pomerantz1 and DS Strayer1,2 1The Dorrance H Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine; and 2Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA Human immunodeficiency virus type I (HIV-1) encodes the SFv-IN was confirmed by Western blotting and several proteins that are packaged into virus particles. Inte- immunofluorescence staining, which showed that Ͼ90% of grase (IN) is an essential retroviral enzyme, which has SupT1 T-lymphocytic cells treated with SV(Aw) expressed been a target for developing agents to inhibit virus repli- the SFv-IN protein without selection. When challenged, cation. In previous studies, we showed that intracellular HIV-1 replication, as measured by HIV-1 p24 antigen expression of single-chain variable antibody fragments expression and syncytium formation, was potently inhibited (SFvs) that bind IN, delivered via retroviral expression vec- in cells expressing SV40-delivered SFv-IN. Levels of inhi- tors, provided resistance to productive HIV-1 infection in bition of HIV-1 infection achieved using this approach were T-lymphocytic cells. In the current studies, we evaluated comparable to those achieved using murine leukemia virus simian-virus 40 (SV40) as a delivery vehicle for anti-IN (MLV) as a transduction vector, the major difference being therapy of HIV-1 infection.
    [Show full text]
  • Type of the Paper (Article
    Viruses 2018 – Breakthroughs in Viral Replication Faculty of Biology University of Barcelona Spain 7 – 9 February 2018 Conference Chair Eric O. Freed Conference Co-Chair Albert Bosch Organised by Conference Secretariat Antonio Peteira Man Luo George Andrianou Nikoleta Kiapidou Kristjana Xhuxhi Pablo Velázquez Lucia Russo Sara Martínez Lynn Huang Sarai Rodríguez Viruses 2018 – Breakthroughs in Viral Replication 1 CONTENTS Abridged Programme 5 Conference Programme 6 Welcome 13 General Information 15 Abstracts – Session 1 25 General Topics in Virology Abstracts – Session 2 45 Structural Virology Abstracts – Session 3 67 Virus Replication Compartments Abstracts – Session 4 89 Replication and Pathogenesis of RNA viruses Abstracts – Session 5 105 Genome Packaging and Replication/Assembly Abstracts – Session 6 127 Antiviral Innate Immunity and Viral Pathogenesis Abstracts – Poster Exhibition 147 List of Participants 297 Viruses 2018 – Breakthroughs in Viral Replication 3 Viruses 2018 – Breakthroughs in Viral Replication 7 – 9 February 2018, Barcelona, Spain Wednesday Thursday Friday 7 February 2018 8 February 2018 9 February 2018 S3. Virus S5. Genome Check-in Replication Packaging and Compartments Replication/Assembly Opening Ceremony S1. General Topics in Virology Morning Coffee Break S1. General Topics S3. Virus S5. Genome in Virology Replication Packaging and Compartments Replication/Assembly Lunch S2. Structural S4. Replication and S6. Antiviral Innate Virology Pathogenesis of Immunity and Viral RNA Viruses Pathogenesis Coffee Break Apéro and Poster Coffee Break Session S2. Structural S6. Antiviral Innate Virology Immunity and Viral Afternoon Conference Group Pathogenesis Photograph Closing Remarks Conference Dinner Wednesday 7 February 2018: 08:00 - 12:30 / 14:00 - 18:00 / Conference Dinner: 20:30 Thursday 8 February 2018: 08:30 - 12:30 / 14:00 - 18:30 Friday 9 February 2018: 08:30 - 12:30 / 14:00 - 18:15 Viruses 2018 – Breakthroughs in Viral Replication 5 Conference Programme Wednesday 7 February 08:00 – 08:45 Check-in 08:45 – 09:00 Opening Ceremony by Eric O.
    [Show full text]
  • Hepatitis B Virus X Protein Inhibits P53 Sequence-Specific DNA Binding
    Proc. Nati. Acad. Sci. USA Vol. 91, pp. 2230-2234, March 1994 Medical Sciences Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3 XIN WEI WANG*, KATHLEEN FORRESTER*, HEIDI YEH*, MARK A. FEITELSONt, JEN-REN GUI, AND CURTIS C. HARRIS*§ *Laboratory of Human Carcinogenesis, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; tDepartment of Pathology and Cell Biology, Jefferson Medical College, Philadelphia, PA 19107; and tDepartment of Molecular Biology and Biochemistry, Shanghai Cancer Institute, Shanghai, People's Republic of China. Communicated by Bert Vogelstein, December 27, 1993 (receivedfor review December 9, 1993) ABSTRACT Chronic active hepatitis caused by infection about the role of HBX in HCC development. In this report, with hepatitis B virus, a DNA virus, is a major risk factor for we present results consistent with the hypothesis that HBX human hepatocellular carcinoma. Since the oncogenicity of binds to p53 and abrogates its normal cellular functions. several DNA viruses is dependent on the interaction of their viral oncoproteins with cellular tumor-suppressor gene prod- MATERIAL AND METHODS ucts, we investigated the interaction between hepatitis B virus X protein (HBX) and human wild-type p53 protein. HBX Plasmids. Plasmid constructs encoding GST-p53-WT, con- complexes with the wild-type p53 protein and inhibits its taining glutathione S-transferase (GST) fused to human wild- sequence-specific DNA binding in vitro. HBX expresslin also type p53, and GST-p53-135Y, containing GST fused to the inhibits p53-mediated transcrptional activation in vivo and the mutant p53 containing a His -* Tyr mutation at codon 135, in vitro asoition of p53 and ERCC3, a general transcription were provided by Jon Huibregtse (National Cancer Institute) factor involved in nucleotide excision repair.
    [Show full text]
  • A SARS-Cov-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
    A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing Supplementary Information Supplementary Discussion All SARS-CoV-2 protein and gene functions described in the subnetwork appendices, including the text below and the text found in the individual bait subnetworks, are based on the functions of homologous genes from other coronavirus species. These are mainly from SARS-CoV and MERS-CoV, but when available and applicable other related viruses were used to provide insight into function. The SARS-CoV-2 proteins and genes listed here were designed and researched based on the gene alignments provided by Chan et. al. 1 2020 .​ Though we are reasonably sure the genes here are well annotated, we want to note that not every ​ protein has been verified to be expressed or functional during SARS-CoV-2 infections, either in vitro or in vivo. ​ ​ In an effort to be as comprehensive and transparent as possible, we are reporting the sub-networks of these functionally unverified proteins along with the other SARS-CoV-2 proteins. In such cases, we have made notes within the text below, and on the corresponding subnetwork figures, and would advise that more caution be taken when examining these proteins and their molecular interactions. Due to practical limits in our sample preparation and data collection process, we were unable to generate data for proteins corresponding to Nsp3, Orf7b, and Nsp16. Therefore these three genes have been left out of the following literature review of the SARS-CoV-2 proteins and the protein-protein interactions (PPIs) identified in this study.
    [Show full text]
  • Viroporins: Structures and Functions Beyond Cell Membrane Permeabilization
    Editorial Viroporins: Structures and Functions beyond Cell Membrane Permeabilization José Luis Nieva 1,* and Luis Carrasco 2,* Received: 17 September 2015 ; Accepted: 21 September 2015 ; Published: 29 September 2015 Academic Editor: Eric O. Freed 1 Biophysics Unit (CSIC, UPV/EHU) and Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), P.O. Box 644, 48080 Bilbao, Spain 2 Centro de Biología Molecular Severo Ochoa (CSIC, UAM), c/Nicolás Cabrera, 1, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain * Correspondence: [email protected] (J.L.N.); [email protected] (L.C.); Tel.: +34-94-601-3353 (J.L.N.); +34-91-497-8450 (L.C.) Viroporins represent an interesting group of viral proteins that exhibit two sets of functions. First, they participate in several viral processes that are necessary for efficient production of virus progeny. Besides, viroporins interfere with a number of cellular functions, thus contributing to viral cytopathogenicity. Twenty years have elapsed from the first review on viroporins [1]; since then several reviews have covered the advances on viroporin structure and functioning [2–8]. This Special Issue updates and revises new emerging roles of viroporins, highlighting their potential use as antiviral targets and in vaccine development. Viroporin structure. Viroporins are usually short proteins with at least one hydrophobic amphipathic helix. Homo-oligomerization is achieved by helix–helix interactions in membranes rendering higher order structures, forming aqueous pores. Progress in viroporin structures during the last 2–3 years has in some instances provided a detailed knowledge of their functional architecture, including the fine definition of binding sites for effective inhibitors.
    [Show full text]
  • Opportunistic Intruders: How Viruses Orchestrate ER Functions to Infect Cells
    REVIEWS Opportunistic intruders: how viruses orchestrate ER functions to infect cells Madhu Sudhan Ravindran*, Parikshit Bagchi*, Corey Nathaniel Cunningham and Billy Tsai Abstract | Viruses subvert the functions of their host cells to replicate and form new viral progeny. The endoplasmic reticulum (ER) has been identified as a central organelle that governs the intracellular interplay between viruses and hosts. In this Review, we analyse how viruses from vastly different families converge on this unique intracellular organelle during infection, co‑opting some of the endogenous functions of the ER to promote distinct steps of the viral life cycle from entry and replication to assembly and egress. The ER can act as the common denominator during infection for diverse virus families, thereby providing a shared principle that underlies the apparent complexity of relationships between viruses and host cells. As a plethora of information illuminating the molecular and cellular basis of virus–ER interactions has become available, these insights may lead to the development of crucial therapeutic agents. Morphogenesis Viruses have evolved sophisticated strategies to establish The ER is a membranous system consisting of the The process by which a virus infection. Some viruses bind to cellular receptors and outer nuclear envelope that is contiguous with an intri‑ particle changes its shape and initiate entry, whereas others hijack cellular factors that cate network of tubules and sheets1, which are shaped by structure. disassemble the virus particle to facilitate entry. After resident factors in the ER2–4. The morphology of the ER SEC61 translocation delivering the viral genetic material into the host cell and is highly dynamic and experiences constant structural channel the translation of the viral genes, the resulting proteins rearrangements, enabling the ER to carry out a myriad An endoplasmic reticulum either become part of a new virus particle (or particles) of functions5.
    [Show full text]
  • NSP4)-Induced Intrinsic Apoptosis
    viruses Article Viperin, an IFN-Stimulated Protein, Delays Rotavirus Release by Inhibiting Non-Structural Protein 4 (NSP4)-Induced Intrinsic Apoptosis Rakesh Sarkar †, Satabdi Nandi †, Mahadeb Lo, Animesh Gope and Mamta Chawla-Sarkar * Division of Virology, National Institute of Cholera and Enteric Diseases, P-33, C.I.T. Road Scheme-XM, Beliaghata, Kolkata 700010, India; [email protected] (R.S.); [email protected] (S.N.); [email protected] (M.L.); [email protected] (A.G.) * Correspondence: [email protected]; Tel.: +91-33-2353-7470; Fax: +91-33-2370-5066 † These authors contributed equally to this work. Abstract: Viral infections lead to expeditious activation of the host’s innate immune responses, most importantly the interferon (IFN) response, which manifests a network of interferon-stimulated genes (ISGs) that constrain escalating virus replication by fashioning an ill-disposed environment. Interestingly, most viruses, including rotavirus, have evolved numerous strategies to evade or subvert host immune responses to establish successful infection. Several studies have documented the induction of ISGs during rotavirus infection. In this study, we evaluated the induction and antiviral potential of viperin, an ISG, during rotavirus infection. We observed that rotavirus infection, in a stain independent manner, resulted in progressive upregulation of viperin at increasing time points post-infection. Knockdown of viperin had no significant consequence on the production of total Citation: Sarkar, R.; Nandi, S.; Lo, infectious virus particles. Interestingly, substantial escalation in progeny virus release was observed M.; Gope, A.; Chawla-Sarkar, M. upon viperin knockdown, suggesting the antagonistic role of viperin in rotavirus release. Subsequent Viperin, an IFN-Stimulated Protein, studies unveiled that RV-NSP4 triggered relocalization of viperin from the ER, the normal residence Delays Rotavirus Release by Inhibiting of viperin, to mitochondria during infection.
    [Show full text]
  • Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2016/05/18/mol.115.102731.DC1 1521-0111/90/2/80–95$25.00 http://dx.doi.org/10.1124/mol.115.102731 MOLECULAR PHARMACOLOGY Mol Pharmacol 90:80–95, August 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride s Pouria H. Jalily, Jodene Eldstrom, Scott C. Miller, Daniel C. Kwan, Sheldon S. -H. Tai, Doug Chou, Masahiro Niikura, Ian Tietjen, and David Fedida Department of Anesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver (P.H.J., J.E., S.C.M., D.C.K., D.C., I.T., D.F.), and Faculty of Health Sciences, Simon Fraser University, Burnaby (S.S.-H.T., M.N., I.T.), British Columbia, Canada Received December 7, 2015; accepted May 12, 2016 Downloaded from ABSTRACT The increasing prevalence of influenza viruses with resistance to [1,19-biphenyl]-4-carboxylate (27) acts both on adamantane- approved antivirals highlights the need for new anti-influenza sensitive and a resistant M2 variant encoding a serine to asparagine therapeutics. Here we describe the functional properties of hexam- 31 mutation (S31N) with improved efficacy over amantadine and – 5 m m ethylene amiloride (HMA) derived compounds that inhibit the wild- HMA (IC50 0.6 Mand4.4 M, respectively). Whereas 9 inhibited molpharm.aspetjournals.org type and adamantane-resistant forms of the influenza A M2 ion in vitro replication of influenza virus encoding wild-type M2 (EC50 5 channel.
    [Show full text]
  • PP2A-Dependent Disruption of Centrosome Replication and Cytoskeleton Organization in Drosophila by SV40 Small Tumor Antigen
    Oncogene (2008) 27, 6334–6346 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $32.00 www.nature.com/onc ORIGINAL ARTICLE PP2A-dependent disruption of centrosome replication and cytoskeleton organization in Drosophila by SV40 small tumor antigen S Kotadia1,LRKao1, SA Comerford2, RT Jones1, RE Hammer3 and TL Megraw1 1Department of Pharmacology, The Cecil and Ida Green Center for Reproductive Biology Sciences, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA; 2Department of Molecular Genetics, The Cecil and Ida Green Center for Reproductive Biology Sciences, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA and 3Department of Biochemistry, The Cecil and Ida Green Center for Reproductive Biology Sciences, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA Viruses of the DNA tumor virus family share the ability to cell-cycle and apoptosis regulation, viral oncoproteins transform vertebrate cells through the action of virus- transform cells. Investigation of DNA tumor virus encoded tumor antigens that interfere with normal cell oncoproteins has led to the identification of many physiology. They accomplish this very efficiently by fundamental mechanisms of tumor suppression (Lavia inhibiting endogenous tumor suppressor proteins that et al., 2003; Ahuja et al., 2005). By altering the activity control cell proliferation and apoptosis. Simian virus 40 of p53, retinoblastoma protein and serine/threonine (SV40) encodes two oncoproteins, large tumor antigen, protein phosphatase 2A (PP2A), three key tumor which directly inhibits the tumor suppressors p53 and Rb, suppressors, SV40 can cause tumor formation in and small tumor antigen (ST), which interferes with transgenic mouse models (Ahuja et al., 2005; Arroyo serine/threonine protein phosphatase 2A (PP2A).
    [Show full text]